Clinical Trials Unit
Stanford University School of Medicine's Center for Advanced Dermatologic Investigation is the Dermatology Department's clinical trials unit.
The Center is home to 12-15 ongoing clinical studies, investigating the safety and efficacy of new and currently available drugs and over-the-counter medications. The Center works with Stanford's own panel on medical research, leading pharmaceutical companies,and the Food and Drug Administration to safely and ethically expand the medical field's knowledge of dermatologic treatments. New studies begin regularly, and the Center continues to recruit patients with skin aging, sun damage, skin cancer (including basal cell carcinomas), psoriasis, atopic dermatitis, rosacea, and other dermatologic diseases for ongoing studies.
Skin Aging Studies
We seek to understand the human aging processes as it relates to skin on a fundamental level. To this end, our studies focus on clinical and translational research efforts ranging from: (1) the analysis of gene changes which predispose individuals to exceptionally youthful skin to (2) molecular signatures that may be biomarkers for aging skin to (3) the careful study of new candidate agents which might affect the skin aging process.
Nonmelanoma Skin Cancer
Recent advances in our understanding of basal cell skin cancer biology have enabled the development of cutting edge study drugs which combat tumor growth. We are currently home to a number of clinical trials at the forefront of potential therapy for advanced or metastatic basal cell cancer. In addition, we seek to understand the biology of basal cell skin cancers and to identify molecular predictors for treatment success.
Acne Rosecea
This is a common and frustrating chronic inflammatory condition of the face, usually affecting older individuals. The causes of this complex condition are the subject of much study. Our clinical studies seek to identify new topical or oral medications to improve the symptoms of acne rosacea.
Contact
For more information, please email dermtrials@stanford.edu
Featured Clinical Trials
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
This is a nonrandomized study of ruxolitinib in combination with a standard multi-agent chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (ruxolitinib) in combination with the chemotherapy regimen. Part 2 will evaluate the efficacy of combination chemotherapy and ruxolitinib at the recommended dose determined in Part 1.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Ruxolitinib
- drug: Asparaginase Erwinia Chrysanthemi
- drug: Cyclophosphamide
- drug: Cytarabine
- drug: Dexamethasone
- drug: Doxorubicin
- drug: Leucovorin Calcium
- drug: Mercaptopurine
- drug: Methotrexate
- drug: Pegaspargase
- drug: Prednisone
- drug: Thioguanine
- drug: Vincristine Sulfate
Eligibility
Inclusion Criteria:
- Eligible for study when participant is 1 year to 21 years at the time of diagnosis
- Eligible Ages in Canada; 2 years to 21 years
- De novo high-risk (HR) Ph-like B-ALL for which any of following criteria are present
at diagnosis:
- Age ≥ 10 years
- White blood cell (WBC) ≥ 50 × 10^3/μL
- CNS3 leukemia at diagnosis
- Systemic steroid pretreatment without presteroid WBC documentation
- Diagnostic bone marrow or peripheral blood sample must have gene expression profiling
and downstream genetic testing performed by submitting diagnostic specimens under the
COG AALL08B1 or APEC14B1 biology studies, or AALL1131 or its successor study.
Specimens must demonstrate a Ph-like expression profile (ie, LDA-positive) as tested
by low density microarray testing at the COG ALL reference laboratory or TriCore
laboratory at the University of New Mexico AND must contain 1 of the following genetic
lesions: (determined at COG ALL reference laboratories, or equivalent
CAP/CLIA-certified laboratories approved by the medical monitor:
1. CRLF2 rearrangement with confirmed JAK1 or JAK2 mutation (JAK+)
2. CRLF2 rearrangement without JAK mutation
3. Other JAK pathway alterations (eg, JAK2 fusions, EPOR fusions, SH2B3 deletions,
IL7RA mutations) with or without CRLF2-R, or CRLF2-R with unknown JAK status as
determined by a COG ALL Reference Laboratory
- Completed a 4-drug Induction therapy regimen (modified aBFM regimen or equivalent) in
Study AALL1131 or its successor study, or as per the institutional standard of care
for HR B-ALL and have had end-Induction minimal residual disease (MRD) assessed
- Male and female subjects of reproductive non childbearing potential or willing to take
appropriate precautions to avoid pregnancy or fathering a child for the duration of
study participation
Exclusion Criteria:
- Receipt of any other cytotoxic chemotherapy before Induction therapy, with exception
of hydroxyurea or steroid pretreatment
- Trisomy 21 (Down syndrome)
- BCR-ABL1-rearranged (Ph+) ALL
- Calculated creatinine clearance or radioisotope glomerular filtration rate < 70
mL/min/1.73 m^2
- Alanine aminotransferase ≥ 5 × upper limit of normal (ULN) for age
- Direct bilirubin ≥ 1.5 × ULN (may be assumed if total bilirubin is below ULN)
- History or evidence of cirrhosis
- Platelet count < 75 × 10^3/μL
- Absolute neutrophil count (ANC) < 750/μL
- Positive screen for hepatitis B or C
- Known human immunodeficiency virus infection
Ages Eligible for Study
1 Year - 21 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Zeel Patel
650-736-2563
I'm interested
Psoriasis Clinical Trials
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
This is a nonrandomized study of ruxolitinib in combination with a standard multi-agent chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (ruxolitinib) in combination with the chemotherapy regimen. Part 2 will evaluate the efficacy of combination chemotherapy and ruxolitinib at the recommended dose determined in Part 1.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Ruxolitinib
- drug: Asparaginase Erwinia Chrysanthemi
- drug: Cyclophosphamide
- drug: Cytarabine
- drug: Dexamethasone
- drug: Doxorubicin
- drug: Leucovorin Calcium
- drug: Mercaptopurine
- drug: Methotrexate
- drug: Pegaspargase
- drug: Prednisone
- drug: Thioguanine
- drug: Vincristine Sulfate
Eligibility
Inclusion Criteria:
- Eligible for study when participant is 1 year to 21 years at the time of diagnosis
- Eligible Ages in Canada; 2 years to 21 years
- De novo high-risk (HR) Ph-like B-ALL for which any of following criteria are present
at diagnosis:
- Age ≥ 10 years
- White blood cell (WBC) ≥ 50 × 10^3/μL
- CNS3 leukemia at diagnosis
- Systemic steroid pretreatment without presteroid WBC documentation
- Diagnostic bone marrow or peripheral blood sample must have gene expression profiling
and downstream genetic testing performed by submitting diagnostic specimens under the
COG AALL08B1 or APEC14B1 biology studies, or AALL1131 or its successor study.
Specimens must demonstrate a Ph-like expression profile (ie, LDA-positive) as tested
by low density microarray testing at the COG ALL reference laboratory or TriCore
laboratory at the University of New Mexico AND must contain 1 of the following genetic
lesions: (determined at COG ALL reference laboratories, or equivalent
CAP/CLIA-certified laboratories approved by the medical monitor:
1. CRLF2 rearrangement with confirmed JAK1 or JAK2 mutation (JAK+)
2. CRLF2 rearrangement without JAK mutation
3. Other JAK pathway alterations (eg, JAK2 fusions, EPOR fusions, SH2B3 deletions,
IL7RA mutations) with or without CRLF2-R, or CRLF2-R with unknown JAK status as
determined by a COG ALL Reference Laboratory
- Completed a 4-drug Induction therapy regimen (modified aBFM regimen or equivalent) in
Study AALL1131 or its successor study, or as per the institutional standard of care
for HR B-ALL and have had end-Induction minimal residual disease (MRD) assessed
- Male and female subjects of reproductive non childbearing potential or willing to take
appropriate precautions to avoid pregnancy or fathering a child for the duration of
study participation
Exclusion Criteria:
- Receipt of any other cytotoxic chemotherapy before Induction therapy, with exception
of hydroxyurea or steroid pretreatment
- Trisomy 21 (Down syndrome)
- BCR-ABL1-rearranged (Ph+) ALL
- Calculated creatinine clearance or radioisotope glomerular filtration rate < 70
mL/min/1.73 m^2
- Alanine aminotransferase ≥ 5 × upper limit of normal (ULN) for age
- Direct bilirubin ≥ 1.5 × ULN (may be assumed if total bilirubin is below ULN)
- History or evidence of cirrhosis
- Platelet count < 75 × 10^3/μL
- Absolute neutrophil count (ANC) < 750/μL
- Positive screen for hepatitis B or C
- Known human immunodeficiency virus infection
Ages Eligible for Study
1 Year - 21 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Zeel Patel
650-736-2563
I'm interested
Dermatology Clinical Trials
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
This is a nonrandomized study of ruxolitinib in combination with a standard multi-agent chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (ruxolitinib) in combination with the chemotherapy regimen. Part 2 will evaluate the efficacy of combination chemotherapy and ruxolitinib at the recommended dose determined in Part 1.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Ruxolitinib
- drug: Asparaginase Erwinia Chrysanthemi
- drug: Cyclophosphamide
- drug: Cytarabine
- drug: Dexamethasone
- drug: Doxorubicin
- drug: Leucovorin Calcium
- drug: Mercaptopurine
- drug: Methotrexate
- drug: Pegaspargase
- drug: Prednisone
- drug: Thioguanine
- drug: Vincristine Sulfate
Eligibility
Inclusion Criteria:
- Eligible for study when participant is 1 year to 21 years at the time of diagnosis
- Eligible Ages in Canada; 2 years to 21 years
- De novo high-risk (HR) Ph-like B-ALL for which any of following criteria are present
at diagnosis:
- Age ≥ 10 years
- White blood cell (WBC) ≥ 50 × 10^3/μL
- CNS3 leukemia at diagnosis
- Systemic steroid pretreatment without presteroid WBC documentation
- Diagnostic bone marrow or peripheral blood sample must have gene expression profiling
and downstream genetic testing performed by submitting diagnostic specimens under the
COG AALL08B1 or APEC14B1 biology studies, or AALL1131 or its successor study.
Specimens must demonstrate a Ph-like expression profile (ie, LDA-positive) as tested
by low density microarray testing at the COG ALL reference laboratory or TriCore
laboratory at the University of New Mexico AND must contain 1 of the following genetic
lesions: (determined at COG ALL reference laboratories, or equivalent
CAP/CLIA-certified laboratories approved by the medical monitor:
1. CRLF2 rearrangement with confirmed JAK1 or JAK2 mutation (JAK+)
2. CRLF2 rearrangement without JAK mutation
3. Other JAK pathway alterations (eg, JAK2 fusions, EPOR fusions, SH2B3 deletions,
IL7RA mutations) with or without CRLF2-R, or CRLF2-R with unknown JAK status as
determined by a COG ALL Reference Laboratory
- Completed a 4-drug Induction therapy regimen (modified aBFM regimen or equivalent) in
Study AALL1131 or its successor study, or as per the institutional standard of care
for HR B-ALL and have had end-Induction minimal residual disease (MRD) assessed
- Male and female subjects of reproductive non childbearing potential or willing to take
appropriate precautions to avoid pregnancy or fathering a child for the duration of
study participation
Exclusion Criteria:
- Receipt of any other cytotoxic chemotherapy before Induction therapy, with exception
of hydroxyurea or steroid pretreatment
- Trisomy 21 (Down syndrome)
- BCR-ABL1-rearranged (Ph+) ALL
- Calculated creatinine clearance or radioisotope glomerular filtration rate < 70
mL/min/1.73 m^2
- Alanine aminotransferase ≥ 5 × upper limit of normal (ULN) for age
- Direct bilirubin ≥ 1.5 × ULN (may be assumed if total bilirubin is below ULN)
- History or evidence of cirrhosis
- Platelet count < 75 × 10^3/μL
- Absolute neutrophil count (ANC) < 750/μL
- Positive screen for hepatitis B or C
- Known human immunodeficiency virus infection
Ages Eligible for Study
1 Year - 21 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Zeel Patel
650-736-2563
I'm interested
Pediatric Dermatology Clinical Trials
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
This is a nonrandomized study of ruxolitinib in combination with a standard multi-agent chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (ruxolitinib) in combination with the chemotherapy regimen. Part 2 will evaluate the efficacy of combination chemotherapy and ruxolitinib at the recommended dose determined in Part 1.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Ruxolitinib
- drug: Asparaginase Erwinia Chrysanthemi
- drug: Cyclophosphamide
- drug: Cytarabine
- drug: Dexamethasone
- drug: Doxorubicin
- drug: Leucovorin Calcium
- drug: Mercaptopurine
- drug: Methotrexate
- drug: Pegaspargase
- drug: Prednisone
- drug: Thioguanine
- drug: Vincristine Sulfate
Eligibility
Inclusion Criteria:
- Eligible for study when participant is 1 year to 21 years at the time of diagnosis
- Eligible Ages in Canada; 2 years to 21 years
- De novo high-risk (HR) Ph-like B-ALL for which any of following criteria are present
at diagnosis:
- Age ≥ 10 years
- White blood cell (WBC) ≥ 50 × 10^3/μL
- CNS3 leukemia at diagnosis
- Systemic steroid pretreatment without presteroid WBC documentation
- Diagnostic bone marrow or peripheral blood sample must have gene expression profiling
and downstream genetic testing performed by submitting diagnostic specimens under the
COG AALL08B1 or APEC14B1 biology studies, or AALL1131 or its successor study.
Specimens must demonstrate a Ph-like expression profile (ie, LDA-positive) as tested
by low density microarray testing at the COG ALL reference laboratory or TriCore
laboratory at the University of New Mexico AND must contain 1 of the following genetic
lesions: (determined at COG ALL reference laboratories, or equivalent
CAP/CLIA-certified laboratories approved by the medical monitor:
1. CRLF2 rearrangement with confirmed JAK1 or JAK2 mutation (JAK+)
2. CRLF2 rearrangement without JAK mutation
3. Other JAK pathway alterations (eg, JAK2 fusions, EPOR fusions, SH2B3 deletions,
IL7RA mutations) with or without CRLF2-R, or CRLF2-R with unknown JAK status as
determined by a COG ALL Reference Laboratory
- Completed a 4-drug Induction therapy regimen (modified aBFM regimen or equivalent) in
Study AALL1131 or its successor study, or as per the institutional standard of care
for HR B-ALL and have had end-Induction minimal residual disease (MRD) assessed
- Male and female subjects of reproductive non childbearing potential or willing to take
appropriate precautions to avoid pregnancy or fathering a child for the duration of
study participation
Exclusion Criteria:
- Receipt of any other cytotoxic chemotherapy before Induction therapy, with exception
of hydroxyurea or steroid pretreatment
- Trisomy 21 (Down syndrome)
- BCR-ABL1-rearranged (Ph+) ALL
- Calculated creatinine clearance or radioisotope glomerular filtration rate < 70
mL/min/1.73 m^2
- Alanine aminotransferase ≥ 5 × upper limit of normal (ULN) for age
- Direct bilirubin ≥ 1.5 × ULN (may be assumed if total bilirubin is below ULN)
- History or evidence of cirrhosis
- Platelet count < 75 × 10^3/μL
- Absolute neutrophil count (ANC) < 750/μL
- Positive screen for hepatitis B or C
- Known human immunodeficiency virus infection
Ages Eligible for Study
1 Year - 21 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Zeel Patel
650-736-2563
I'm interested
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
This is a nonrandomized study of ruxolitinib in combination with a standard multi-agent chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (ruxolitinib) in combination with the chemotherapy regimen. Part 2 will evaluate the efficacy of combination chemotherapy and ruxolitinib at the recommended dose determined in Part 1.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Ruxolitinib
- drug: Asparaginase Erwinia Chrysanthemi
- drug: Cyclophosphamide
- drug: Cytarabine
- drug: Dexamethasone
- drug: Doxorubicin
- drug: Leucovorin Calcium
- drug: Mercaptopurine
- drug: Methotrexate
- drug: Pegaspargase
- drug: Prednisone
- drug: Thioguanine
- drug: Vincristine Sulfate
Eligibility
Inclusion Criteria:
- Eligible for study when participant is 1 year to 21 years at the time of diagnosis
- Eligible Ages in Canada; 2 years to 21 years
- De novo high-risk (HR) Ph-like B-ALL for which any of following criteria are present
at diagnosis:
- Age ≥ 10 years
- White blood cell (WBC) ≥ 50 × 10^3/μL
- CNS3 leukemia at diagnosis
- Systemic steroid pretreatment without presteroid WBC documentation
- Diagnostic bone marrow or peripheral blood sample must have gene expression profiling
and downstream genetic testing performed by submitting diagnostic specimens under the
COG AALL08B1 or APEC14B1 biology studies, or AALL1131 or its successor study.
Specimens must demonstrate a Ph-like expression profile (ie, LDA-positive) as tested
by low density microarray testing at the COG ALL reference laboratory or TriCore
laboratory at the University of New Mexico AND must contain 1 of the following genetic
lesions: (determined at COG ALL reference laboratories, or equivalent
CAP/CLIA-certified laboratories approved by the medical monitor:
1. CRLF2 rearrangement with confirmed JAK1 or JAK2 mutation (JAK+)
2. CRLF2 rearrangement without JAK mutation
3. Other JAK pathway alterations (eg, JAK2 fusions, EPOR fusions, SH2B3 deletions,
IL7RA mutations) with or without CRLF2-R, or CRLF2-R with unknown JAK status as
determined by a COG ALL Reference Laboratory
- Completed a 4-drug Induction therapy regimen (modified aBFM regimen or equivalent) in
Study AALL1131 or its successor study, or as per the institutional standard of care
for HR B-ALL and have had end-Induction minimal residual disease (MRD) assessed
- Male and female subjects of reproductive non childbearing potential or willing to take
appropriate precautions to avoid pregnancy or fathering a child for the duration of
study participation
Exclusion Criteria:
- Receipt of any other cytotoxic chemotherapy before Induction therapy, with exception
of hydroxyurea or steroid pretreatment
- Trisomy 21 (Down syndrome)
- BCR-ABL1-rearranged (Ph+) ALL
- Calculated creatinine clearance or radioisotope glomerular filtration rate < 70
mL/min/1.73 m^2
- Alanine aminotransferase ≥ 5 × upper limit of normal (ULN) for age
- Direct bilirubin ≥ 1.5 × ULN (may be assumed if total bilirubin is below ULN)
- History or evidence of cirrhosis
- Platelet count < 75 × 10^3/μL
- Absolute neutrophil count (ANC) < 750/μL
- Positive screen for hepatitis B or C
- Known human immunodeficiency virus infection
Ages Eligible for Study
1 Year - 21 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Zeel Patel
650-736-2563
I'm interested
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
This is a nonrandomized study of ruxolitinib in combination with a standard multi-agent chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (ruxolitinib) in combination with the chemotherapy regimen. Part 2 will evaluate the efficacy of combination chemotherapy and ruxolitinib at the recommended dose determined in Part 1.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Ruxolitinib
- drug: Asparaginase Erwinia Chrysanthemi
- drug: Cyclophosphamide
- drug: Cytarabine
- drug: Dexamethasone
- drug: Doxorubicin
- drug: Leucovorin Calcium
- drug: Mercaptopurine
- drug: Methotrexate
- drug: Pegaspargase
- drug: Prednisone
- drug: Thioguanine
- drug: Vincristine Sulfate
Eligibility
Inclusion Criteria:
- Eligible for study when participant is 1 year to 21 years at the time of diagnosis
- Eligible Ages in Canada; 2 years to 21 years
- De novo high-risk (HR) Ph-like B-ALL for which any of following criteria are present
at diagnosis:
- Age ≥ 10 years
- White blood cell (WBC) ≥ 50 × 10^3/μL
- CNS3 leukemia at diagnosis
- Systemic steroid pretreatment without presteroid WBC documentation
- Diagnostic bone marrow or peripheral blood sample must have gene expression profiling
and downstream genetic testing performed by submitting diagnostic specimens under the
COG AALL08B1 or APEC14B1 biology studies, or AALL1131 or its successor study.
Specimens must demonstrate a Ph-like expression profile (ie, LDA-positive) as tested
by low density microarray testing at the COG ALL reference laboratory or TriCore
laboratory at the University of New Mexico AND must contain 1 of the following genetic
lesions: (determined at COG ALL reference laboratories, or equivalent
CAP/CLIA-certified laboratories approved by the medical monitor:
1. CRLF2 rearrangement with confirmed JAK1 or JAK2 mutation (JAK+)
2. CRLF2 rearrangement without JAK mutation
3. Other JAK pathway alterations (eg, JAK2 fusions, EPOR fusions, SH2B3 deletions,
IL7RA mutations) with or without CRLF2-R, or CRLF2-R with unknown JAK status as
determined by a COG ALL Reference Laboratory
- Completed a 4-drug Induction therapy regimen (modified aBFM regimen or equivalent) in
Study AALL1131 or its successor study, or as per the institutional standard of care
for HR B-ALL and have had end-Induction minimal residual disease (MRD) assessed
- Male and female subjects of reproductive non childbearing potential or willing to take
appropriate precautions to avoid pregnancy or fathering a child for the duration of
study participation
Exclusion Criteria:
- Receipt of any other cytotoxic chemotherapy before Induction therapy, with exception
of hydroxyurea or steroid pretreatment
- Trisomy 21 (Down syndrome)
- BCR-ABL1-rearranged (Ph+) ALL
- Calculated creatinine clearance or radioisotope glomerular filtration rate < 70
mL/min/1.73 m^2
- Alanine aminotransferase ≥ 5 × upper limit of normal (ULN) for age
- Direct bilirubin ≥ 1.5 × ULN (may be assumed if total bilirubin is below ULN)
- History or evidence of cirrhosis
- Platelet count < 75 × 10^3/μL
- Absolute neutrophil count (ANC) < 750/μL
- Positive screen for hepatitis B or C
- Known human immunodeficiency virus infection
Ages Eligible for Study
1 Year - 21 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Zeel Patel
650-736-2563
I'm interested